Emma Betuel

The Latest from Emma Betuel

Shares of protein discovery platform Absci pop in market debut

Absci Corp., a Vancouver company behind a multifaceted drug development platform, went public on Thursday. It’s another sign of snowballing interest in new approaches to drug development — a t

Biosafety startup R-Zero acquires CoWorkr to create an ‘OS for the workplace’

On Tuesday, R-Zero, a pandemic-era biosafety company, announced the acquisition of CoWorkr — a company that develops room occupancy sensors. The acquisition marks a shift in focus for R-Zero as

Sweetch raises $20M for a personalized engagement system designed to boost health outcomes

You’ve just sat down to dinner and your wearable device reminds you to get up and get in your steps for the day. Maybe the app has a point, but odds are you’ll push the notification to the side. T

Massachusetts startup OPT Industries is perfecting a 3D-printed nasal swab for COVID-19 tests

In 2020 and 2021, we all became well-acquainted with nasal swabs. But small sticks we stuck up our noses, it turns out, were harder to come by than anyone could have predicted. A May 2020 survey of 11

Aidoc raises over $66M for AI radiology analysis technology

Aidoc, an artificial intelligence company that develops triage and analysis software, is about to double its funding. On Tuesday, the company announced a round of $66 million. Before that the company

FabricNano raises $12.5M to help scale its cell-free fossil fuel alternative technology

It’s not often that you hear DNA described as a wafer – but that’s the analogy that Grant Aarons, the founder of FabricNano, a cell-free biomanufacturing company uses to describe his company’s

4G Clinical’s clinical trial management software attracts over $200M in new funding

The pandemic significantly changed how we do medical research, and now companies are trying to figure out what trends will stay and which ones will go. One that 4G Clinical is hoping will survive the

As clinical guidelines shift, heart disease screening startup pulls in $43M Series B

Cleerly Coronary, a company that uses A.I powered imaging to analyze heart scans, announced a $43 million Series B funding this week. The funding comes at a moment when it seems that a new way of scre

AI drug discovery platform Insilico Medicine announces $255 million in Series C funding

Insilico Medicine, an AI-based platform for drug development and discovery, announced $255 million in Series C financing on Tuesday. The massive round is reflective of a recent breakthrough for the co

Mobile dialysis startup eyes human trials in 2022 following encouraging animal study

This past year, three sheep in Canada have been wearing their kidneys on their sleeves. Or more aptly, in jackets on their fluffy backs.  These three sheep are part of an ongoing animal study run by

Meet the mobile therapy startup backed by Christian Angermayer’s re:Mind Capital

Mental health startup Ksana Health has received $2 million in seed funding led by re:Mind Capital, the mental health VC arm of Christian Angermayer and Apeiron Investment Group. It’s a move informed

“Alzheimer’s is open for business:” Controversial FDA approval could pave the way for future drugs

On Monday, a 17-year drought in the world of Alzheimer’s drugs ended with the FDA approval of Biogen’s Aduhlem (aducanumab). The controversy behind the FDA’s decision was considerable, but it do

After contentious debate, FDA approves first Alzheimer’s drug since 2003

On Monday, the US Food and Drug Administration granted approval to a keenly-watched Alzheimer’s drug, aducanumab, developed by the drugmaker Biogen. The decision to approve the drug, which was once

Mental health app Wysa raises $5.5M for ’emotionally intelligent’ AI

It’s hard enough to talk about your feelings to a person; Jo Aggarwal, the founder and CEO of Wysa, is hoping you’ll find it easier to confide in a robot. Or, put more specifically, “emotionally

‘It’s almost like placing an IV’: Brain monitoring electrode receives FDA 510(k) clearance

An FDA pathway that’s greased the gears for COVID-19 vaccines and drugs has paved the way for something else: a new take on electroencephalography (EEG), the established brain-monitoring technique i